Cargando…
Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study
BACKGROUND: Uveal melanoma is the most common primary intraocular tumor in adults. In Sweden, at least 100 patients are diagnosed with the disease each year. Almost half of the patients develop metastases, with a median survival time of 1 year once metastases are detected. The primary ocular tumor i...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040135/ https://www.ncbi.nlm.nih.gov/pubmed/36966349 http://dx.doi.org/10.1186/s13063-023-07245-9 |